Walgreens Receives BARDA Project NextGen Award to Conduct Novel COVID-19 Decentralized Clinical Study
Walgreens Receives BARDA Project NextGen Award to Conduct Novel COVID-19 Decentralized Clinical Study
DEERFIELD, Ill. -- JULY 23, 2024-- Walgreens today announced it received a project award valued up to $25 million through the Rapid Response Partnership Vehicle (RRPV) to conduct a Phase IV observational clinical study focused on assessing Correlates of Protection (CoP), known as responses to a vaccine that predict how well a vaccinated person will be protected from future infections, using COVID-19 vaccine data. The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS). This partnership underscores a shared commitment to advancing public health through innovative research and leveraging Walgreens' extensive community pharmacies to increase access and representation in clinical trials.
沃尔格林今天宣布,通过快速响应伙伴关系(RRPV)获得了价值2500万美元的项目奖励,开展第四期观察性临床研究,重点评估相关保护(CoP),即对疫苗的反应,预测受疫苗接种的人在未来感染病毒时的保护效果。RRPV是由美国卫生与公共服务部战略准备和响应管理局(ASPR)下的生物医学高级研究和开发局(BARDA)资助的联合体。这种合作关系凸显了通过创新研究和利用沃尔格林广泛的社区药房来增加接触和参与临床试验的共同承诺。
As a leading community pharmacy and front door to the U.S. healthcare system, Walgreens played a pivotal role in the distribution of COVID-19 vaccines and testing throughout the pandemic. Walgreens has administered over 90 million COVID-19 vaccinations to date, showcasing its capacity to handle large-scale health initiatives. Building on this experience, through this collaboration, the BARDA-funded study will utilize select Walgreens community pharmacies as clinical trial sites to assess the effectiveness of FDA-authorized COVID-19 vaccines. This initiative aims to enhance access to clinical research across diverse patient populations, particularly in communities historically underrepresented in clinical trials.
作为美国领先的社区药房和通往健康医疗系统的大门,沃尔格林在整个大流行期间发挥了关键作用,分发COVID-19疫苗和测试。沃尔格林迄今为止已经进行了9000万次COVID-19疫苗接种,展示了处理大规模卫生计划的能力。通过此次合作,BARDA资助的研究将利用选择的沃尔格林社区药房作为临床试验地点,评估FDA授权的COVID-19疫苗的有效性。这个计划旨在加强跨多样化患者人口的临床研究访问,特别是在历史上参与临床试验较少的社区。
"We are honored to be selected by BARDA and its RRPV for this important study as this is a step forward to utilize public and private partnerships to bring clinical trials into more communities across the country," said Ramita Tandon, chief clinical trials officer at Walgreens. "With our experience in immunizations and trusted relationship with millions of patients and customers, Walgreens is uniquely positioned to support this critical research. As the only retail pharmacy with a national decentralized clinical trial infrastructure and dedicated clinical research staff, we are committed to helping enhance public health preparedness."
“我们很荣幸被BARDA及其RRPV选中参加这项重要研究,这是利用公共和私营合作推广临床试验,把更多的临床试验引入更多社区的一大步,”沃尔格林首席临床试验官拉米塔·坦顿说。“凭借我们在免疫接种方面的经验和与数百万患者和客户的信任关系,沃尔格林有独特的地位来支持这项关键研究。作为唯一一个拥有全国分散式临床试验基础设施和专门的临床研究人员队伍的零售药店,我们致力于帮助提高公共健康准备水平。”
Walgreens will employ a comprehensive approach to participant recruitment, which will leverage its physical footprint in addition to its compliant and secure decentralized clinical trial platform to reach patients where it's most convenient for them. The study will enroll up to 4,000 participants across 20 retail pharmacy locations nationwide, ensuring a diverse and representative study population.
沃尔格林将采用全面的参与者招募方法,利用其物理占地面积以及符合规定和安全的分散式临床试验平台,以最为方便的方式接触到患者。该研究将在全国20个零售药店地点招募最多4,000名参与者,确保招募到多样化和代表性的研究人群。
Funding for this award was received under Project NextGen, a $5 billion initiative by HHS to advance a pipeline of new, innovative vaccines and therapeutics providing broader and more durable protection for COVID-19 than the first-generation COVID vaccines and medicines. BARDA is supporting the development of new vaccines, therapeutics, and enabling technologies to better address the waning immunity and resistance to current and future SARS-CoV2 viral strains.
此项奖励的资金来自3.2亿美元的“NextGen”计划,这是HHS为推进一系列新的创新疫苗和治疗药物而启动的倡议。BARDA正在支持开发新的疫苗、治疗和使能技术,以更好地应对当前和未来的SARS-CoV2病毒株的免疫衰退和抵抗。
This project is being funded with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under Other Transaction (OT) number: 75A50123D00005.
该项目使用来自美国卫生与公共服务部战略准备和响应管理局(ASPR)下的生物医学高级研究和开发局(BARDA)的联合交易(OT)编号:75A50123D00005的联邦资金进行了资助。
About Walgreens
关于沃尔格林 沃尔格林(
Walgreens () is included in the U.S. Retail Pharmacy and U.S. Healthcare segments of Walgreens Boots Alliance, Inc. (Nasdaq: WBA), an integrated healthcare, pharmacy and retail leader. True to its purpose of "more joyful lives through better health," Walgreens has a more than 120-year heritage of caring for communities and providing trusted pharmacy services, and today is playing a greater role as an independent partner of choice offering healthcare services that improve care, lower costs, and help patients. Operating nearly 9,000 retail locations across the U.S. and Puerto Rico, Walgreens is proud to serve nearly 9 million customers and patients daily. The company's pharmacists are playing a more critical role in healthcare than ever before, providing a wide range of pharmacy and healthcare services, including those that drive equitable access to care for some of the nation's most underserved populations. Walgreens offers customers and patients a true omnichannel experience, with fully integrated physical and digital platforms designed to deliver high-quality products and healthcare services. Within the U.S. Healthcare segment, Walgreens portfolio also includes businesses in primary care, multi-specialty, post-acute care, urgent care, specialty pharmacy services, population health and provider enablement.
沃尔格林(Walgreens)是沃尔格林靴子联盟公司(Walgreens Boots Alliance,Inc.,纳斯达克(WBA))的美国零售药店和美国医疗保健部门的一部分,是一家综合医疗保健、药店和零售业的领导者。一直秉承“通过更好的健康实现更加快乐的生活”的宗旨,沃尔格林有超过120年的为社区服务和提供可靠药房服务的历史,今天在作为独立的合作伙伴方面扮演着更为重要的角色,提供有助于改善护理、降低成本并帮助患者的医疗保健服务。在美国及波多黎各境内拥有近9000个零售店铺,沃尔格林自豪地为近900万客户和患者提供服务。该公司的药剂师扮演着比以往任何时候都更为重要的医疗保健角色,提供广泛的药房和医疗保健服务,包括推动为一些国家最贫困的人群实现公平护理所需的服务。沃尔格林为客户和患者提供真正的全渠道体验,拥有完全集成的实体和数字平台,旨在提供高质量的产品和医疗保健服务。在美国医疗保健部门内,沃尔格林的组合还包括初级保健、多科专业、后急诊护理、特别药房服务、人口健康和提供商启用业务。
Media Contact
媒体联系人
Carmen Lopez
media@walgreens.com
卡门·洛佩兹
media@walgreens.com